Results 1 to 10 of about 221 (98)

Сardioprotective agents with biaromatic structure. Part 6. Beta blockers [PDF]

open access: yesФармакокинетика и Фармакодинамика, 2023
β-Blockers are one of the oldest classes of cardioprotectors used in the treatment of cardiovascular diseases. They reduce the heart rate, have a hypotensive effect, inhibit myocardial contractility and have antiarrhythmic properties.
G. V. Mokrov
doaj   +5 more sources

Study of the antiarrhythmic activity of linear alkoxyphenylazalkanes in the model of reperfusion arrythmias in rats [PDF]

open access: yesФармакокинетика и Фармакодинамика, 2023
The antiarrhythmic activity of bis-alkoxyphenyltriazaalkanes 1 and bis-alkoxyphenyldiazaalkanes 2 was analyzed in a model of reperfusion arrhythmia in rats.
V. V. Barchukov   +7 more
doaj   +5 more sources

Сardioprotective agents with biaromatic structure. Part 2. HCN channel blockers [PDF]

open access: yesФармакокинетика и Фармакодинамика, 2022
Hyperpolarization-activated cyclic nucleotide–gated (HCN) channels, primarily their HCN4 subtype, are one of the promising targets for the development of cardioprotective agents.
G. V. Mokrov
doaj   +7 more sources

Сardioprotective agents with biaromatic structure. Part 3. Sodium channel blockers [PDF]

open access: yesФармакокинетика и Фармакодинамика, 2022
This review continues a series of reviews on the analysis of compounds with cardioprotective properties in a number of biaromatic structures, which include a range of sodium channel blockers. Among voltage-gated sodium channels, the Nav1.5 isoform is the
G. V. Mokrov
doaj   +5 more sources

EVALUATION OF CARDIOPROTECTIVE EFFECTS OF THE INCRITIN MIMETICS EXENATIDE AND VILDAGLIPTIN IN THE EXPERIMENT [PDF]

open access: yesResearch Results in Pharmacology, 2017
Introduction: The results of experimental and clinical trials make it clear that incretin mimetics possess pleiotropic effects and demonstrate the value in terms of assessment of their potential opportunities as cardioprotectors.
Alla Tarasova   +5 more
doaj   +7 more sources

Histochemical evaluation of T-2 toxin-induced cardiotoxicity in rats: Semiquantitative analysis [PDF]

open access: yesZbornik Matice Srpske za Prirodne Nauke, 2009
In this study female Wistar rats were treated with T-2 toxin (1 LD50 0.23 mg/kg sc) and sacrificed on days 1, 3, 5, 7, 14, 21, 28 and 60 after the treatment. Control groups of rats were treated by saline (1 ml/kg 0.9% NaCl).
Jaćević Vesna M.   +6 more
doaj   +4 more sources

Сardioprotective agents with biaromatic structure. Part 1. Calcium channel blockers [PDF]

open access: yesФармакокинетика и Фармакодинамика, 2022
Cardiovascular diseases (CVD) are widespread and the leading cause of morbidity and mortality worldwide. Drugs for the treatment of CVD have been developed since the beginning of the 20th century.
G. V. Mokrov
doaj   +3 more sources

Tackling Atherosclerosis via Selected Nutrition. [PDF]

open access: yesInt J Mol Sci, 2022
The development and pathogenesis of atherosclerosis are significantly influenced by lifestyle, particularly nutrition. The modern level of science and technology development promote personalized nutrition as an efficient preventive measure against ...
Vesnina A   +4 more
europepmc   +3 more sources

Сardioprotective agents with biaromatic structure. Part 5. Potassium Kv1.5-channels blockers [PDF]

open access: yesФармакокинетика и Фармакодинамика, 2023
The Kv1.5 potassium channel provides an ultra-rapid delayed rectifier potassium current, IKur, that acts selectively in human atrial cells. This makes selective Kv1.5 blockade a promising approach to control atrial arrhythmias without the adverse ...
G. V. Mokrov
doaj   +3 more sources

Cardiovascular adverse effects associated with the use of anti-HER2 in breast cancer treatment. [PDF]

open access: yesFront Pharmacol, 2023
Background: Cancer represents an important public health problem with increasing incidence, prevalence, and mortality, affecting the entire Western population, especially in developed and developing countries.
Valente PMS   +4 more
europepmc   +3 more sources

Home - About - Disclaimer - Privacy